{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:40:45Z","timestamp":1790894445422,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["AR-041203"],"award-info":[{"award-number":["AR-041203"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options in Rheum"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40674-021-00182-1","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T22:02:40Z","timestamp":1623708160000},"page":"258-271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Inhibiting Interferon Pathways in Dermatomyositis: Rationale and Preliminary Evidence"],"prefix":"10.1007","volume":"7","author":[{"given":"Maria","family":"Casal-Dominguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6338-9218","authenticated-orcid":false,"given":"Iago","family":"Pinal-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"issue":"9","key":"182_CR1","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","volume":"17","author":"A Selva-O\u2019Callaghan","year":"2018","unstructured":"Selva-O\u2019Callaghan A, Pinal-Fernandez I, Trallero-Araguas E, Milisenda JC, Grau-Junyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17(9):816\u201328. https:\/\/doi.org\/10.1016\/S1474-4422(18)30254-0.","journal-title":"Lancet Neurol"},{"issue":"3","key":"182_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s13317-014-0060-4","volume":"5","author":"A Ghirardello","year":"2014","unstructured":"Ghirardello A, Borella E, Beggio M, Franceschini F, Fredi M, Doria A. Myositis autoantibodies and clinical phenotypes. Auto Immun Highlights. 2014;5(3):69\u201375. https:\/\/doi.org\/10.1007\/s13317-014-0060-4.","journal-title":"Auto Immun Highlights"},{"issue":"5","key":"182_CR3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrrheum.2011.39","volume":"7","author":"M Zong","year":"2011","unstructured":"Zong M, Lundberg IE. Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol. 2011;7(5):297\u2013306. https:\/\/doi.org\/10.1038\/nrrheum.2011.39.","journal-title":"Nat Rev Rheumatol"},{"issue":"Pt 7","key":"182_CR4","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1093\/brain\/aww122","volume":"139","author":"R Lahoria","year":"2016","unstructured":"Lahoria R, Selcen D, Engel AG. Microvascular alterations and the role of complement in dermatomyositis. Brain. 2016;139(Pt 7):1891\u2013903. https:\/\/doi.org\/10.1093\/brain\/aww122.","journal-title":"Brain."},{"issue":"7","key":"182_CR5","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/art.24621","volume":"60","author":"S Sato","year":"2009","unstructured":"Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60(7):2193\u2013200. https:\/\/doi.org\/10.1002\/art.24621.","journal-title":"Arthritis Rheum"},{"key":"182_CR6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.4269\/ajtmh.1935.s1-15.675","volume":"15","author":"M Hoskins","year":"1935","unstructured":"Hoskins M. A protective action of neutropic against viscerotropic yellow fever virus in Macacus rhesus. Am J Trop Med Hyg. 1935;15:675\u201380.","journal-title":"Am J Trop Med Hyg"},{"key":"182_CR7","doi-asserted-by":"publisher","unstructured":"De Andrea M, Ravera R, Gioia D, Gariglio M, Landolfo S. The interferon system: an overview. Eur J Paediatr Neurol. 2002;6(Suppl A):A41\u20136; discussion A55-8. https:\/\/doi.org\/10.1053\/ejpn.2002.0573.","DOI":"10.1053\/ejpn.2002.0573"},{"issue":"3","key":"182_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.immuni.2006.08.008","volume":"25","author":"J Vilcek","year":"2006","unstructured":"Vilcek J. Fifty years of interferon research: aiming at a moving target. Immunity. 2006;25(3):343\u20138. https:\/\/doi.org\/10.1016\/j.immuni.2006.08.008.","journal-title":"Immunity."},{"issue":"Suppl 1","key":"182_CR9","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar2881","volume":"12","author":"GD Kalliolias","year":"2010","unstructured":"Kalliolias GD, Ivashkiv LB. Overview of the biology of type I interferons. Arthritis Res Ther. 2010;12(Suppl 1):S1. https:\/\/doi.org\/10.1186\/ar2881.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"182_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1189\/jlb.1208761","volume":"86","author":"M Li","year":"2009","unstructured":"Li M, Liu X, Zhou Y, Su SB. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol. 2009;86(1):23\u201332. https:\/\/doi.org\/10.1189\/jlb.1208761.","journal-title":"J Leukoc Biol"},{"key":"182_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev.biochem.67.1.227","volume":"67","author":"GR Stark","year":"1998","unstructured":"Stark GR, Kerr M, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem. 1998;67:227\u201364.","journal-title":"Annu Rev Biochem"},{"issue":"5","key":"182_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri1604","volume":"5","author":"LC Platanias","year":"2005","unstructured":"Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375\u201386. https:\/\/doi.org\/10.1038\/nri1604.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"182_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","volume":"368","author":"JJ O'Shea","year":"2013","unstructured":"O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368(2):161\u201370. https:\/\/doi.org\/10.1056\/NEJMra1202117.","journal-title":"N Engl J Med"},{"key":"182_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","volume":"16","author":"WJ Leonard","year":"1998","unstructured":"Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol. 1998;16:293\u2013322. https:\/\/doi.org\/10.1146\/annurev.immunol.16.1.293.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"182_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273\u201387. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00754.x.","journal-title":"Immunol Rev"},{"issue":"9","key":"182_CR16","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nrm909","volume":"3","author":"DE Levy","year":"2002","unstructured":"Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651\u201362. https:\/\/doi.org\/10.1038\/nrm909.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"182_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14(1):36\u201349. https:\/\/doi.org\/10.1038\/nri3581.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"182_CR18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1089\/jir.2014.0021","volume":"34","author":"SC Nallar","year":"2014","unstructured":"Nallar SC, Kalvakolanu DV. Interferons, signal transduction pathways, and the central nervous system. J Interf Cytokine Res. 2014;34(8):559\u201376. https:\/\/doi.org\/10.1089\/jir.2014.0021.","journal-title":"J Interf Cytokine Res"},{"issue":"11","key":"182_CR19","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1136\/ard.2011.150326","volume":"70","author":"BW Higgs","year":"2011","unstructured":"Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis. 2011;70(11):2029\u201336. https:\/\/doi.org\/10.1136\/ard.2011.150326.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"182_CR20","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ana.20464","volume":"57","author":"SA Greenberg","year":"2005","unstructured":"Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57(5):664\u201378. https:\/\/doi.org\/10.1002\/ana.20464.","journal-title":"Ann Neurol"},{"issue":"1-2","key":"182_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","volume":"13","author":"EC Baechler","year":"2007","unstructured":"Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007;13(1-2):59\u201368. https:\/\/doi.org\/10.2119\/2006-00085.Baechler.","journal-title":"Mol Med"},{"issue":"11","key":"182_CR22","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1002\/art.22928","volume":"56","author":"RJ Walsh","year":"2007","unstructured":"Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 2007;56(11):3784\u201392. https:\/\/doi.org\/10.1002\/art.22928.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"182_CR23","doi-asserted-by":"publisher","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","volume":"93","author":"I Pinal-Fernandez","year":"2019","unstructured":"\u2022 Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, Pak K, Plotz P, Miller FW, et al. Identification of distinctive interferon gene signatures in different types of myositis. Neurology. 2019;93(12):e1193\u2013e204. https:\/\/doi.org\/10.1212\/WNL.0000000000008128Study describing the activation of the type I and type II interferon pathways in different types in myositis.","journal-title":"Neurology"},{"issue":"6","key":"182_CR24","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/art.24555","volume":"60","author":"TB Niewold","year":"2009","unstructured":"Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM. Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum. 2009;60(6):1815\u201324. https:\/\/doi.org\/10.1002\/art.24555.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"182_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.clim.2006.05.011","volume":"120","author":"KA O'Connor","year":"2006","unstructured":"O'Connor KA, Abbott KA, Sabin B, Kuroda M, Pachman LM. MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol. 2006;120(3):319\u201325. https:\/\/doi.org\/10.1016\/j.clim.2006.05.011.","journal-title":"Clin Immunol"},{"issue":"8","key":"182_CR26","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.4049\/jimmunol.168.8.4154","volume":"168","author":"Z Tezak","year":"2002","unstructured":"Tezak Z, Hoffman EP, Lutz JL, Fedczyna TO, Stephan D, Bremer EG, et al. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol. 2002;168(8):4154\u201363. https:\/\/doi.org\/10.4049\/jimmunol.168.8.4154.","journal-title":"J Immunol"},{"issue":"1","key":"182_CR27","doi-asserted-by":"publisher","first-page":"e29161","DOI":"10.1371\/journal.pone.0029161","volume":"7","author":"D Wong","year":"2012","unstructured":"Wong D, Kea B, Pesich R, Higgs BW, Zhu W, Brown P, et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One. 2012;7(1):e29161. https:\/\/doi.org\/10.1371\/journal.pone.0029161.","journal-title":"PLoS One"},{"issue":"3","key":"182_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/gene.2011.61","volume":"13","author":"SA Greenberg","year":"2012","unstructured":"Greenberg SA, Higgs BW, Morehouse C, Walsh RJ, Kong SW, Brohawn P, et al. Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun. 2012;13(3):207\u201313. https:\/\/doi.org\/10.1038\/gene.2011.61.","journal-title":"Genes Immun"},{"issue":"1","key":"182_CR29","doi-asserted-by":"publisher","first-page":"e000811","DOI":"10.1136\/rmdopen-2018-000811","volume":"5","author":"M Rigolet","year":"2019","unstructured":"\u2022 Rigolet M, Hou C, Baba Amer Y, Aouizerate J, Periou B, Gherardi RK, et al. Distinct interferon signatures stratify inflammatory and dysimmune myopathies. RMD Open. 2019;5(1):e000811. https:\/\/doi.org\/10.1136\/rmdopen-2018-000811Study describing the activation of the type I and type II interferon pathways in different types in myositis.","journal-title":"RMD Open"},{"issue":"3","key":"182_CR30","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jaci.2020.10.022","volume":"147","author":"W Damsky","year":"2020","unstructured":"Damsky W, Peterson D, Ramseier J, Al-Bawardy B, Chun H, Proctor DSV, et al. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. J Allergy Clin Immunol. 2020;147(3):814\u201326. https:\/\/doi.org\/10.1016\/j.jaci.2020.10.022.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"182_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1006\/geno.1996.0520","volume":"37","author":"MC Riedy","year":"1996","unstructured":"Riedy MC, Dutra AS, Blake TB, Modi W, Lal BK, Davis J, et al. Genomic sequence, organization, and chromosomal localization of human JAK3. Genomics. 1996;37(1):57\u201361. https:\/\/doi.org\/10.1006\/geno.1996.0520.","journal-title":"Genomics."},{"issue":"7","key":"182_CR32","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","volume":"186","author":"K Ghoreschi","year":"2011","unstructured":"Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234\u201343. https:\/\/doi.org\/10.4049\/jimmunol.1003668.","journal-title":"J Immunol"},{"issue":"9","key":"182_CR33","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","volume":"14","author":"A Berekmeri","year":"2018","unstructured":"Berekmeri A, Mahmood F, Wittmann M, Helliwell P. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(9):719\u201330. https:\/\/doi.org\/10.1080\/1744666X.2018.1512404.","journal-title":"Expert Rev Clin Immunol"},{"key":"182_CR34","doi-asserted-by":"publisher","unstructured":"Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2014;12(9):1485\u201393 e2. https:\/\/doi.org\/10.1016\/j.cgh.2014.01.029.","DOI":"10.1016\/j.cgh.2014.01.029"},{"key":"182_CR35","unstructured":"Xeljanz [package insert]. Pfizer Inc. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=959."},{"key":"182_CR36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O'Shea","year":"2015","unstructured":"O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311\u201328. https:\/\/doi.org\/10.1146\/annurev-med-051113-024537.","journal-title":"Annu Rev Med"},{"issue":"12","key":"182_CR37","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1002028.","journal-title":"N Engl J Med"},{"issue":"9","key":"182_CR38","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557.","journal-title":"N Engl J Med"},{"issue":"5","key":"182_CR39","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/13543784.2020.1757069","volume":"29","author":"SM Abedin","year":"2020","unstructured":"Abedin SM, Hamadani M. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease. Expert Opin Investig Drugs. 2020;29(5):423\u20137. https:\/\/doi.org\/10.1080\/13543784.2020.1757069.","journal-title":"Expert Opin Investig Drugs"},{"issue":"9","key":"182_CR40","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","volume":"184","author":"JS Fridman","year":"2010","unstructured":"Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184(9):5298\u2013307. https:\/\/doi.org\/10.4049\/jimmunol.0902819.","journal-title":"J Immunol"},{"issue":"12","key":"182_CR41","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/jm401490p","volume":"57","author":"JD Clark","year":"2014","unstructured":"Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023\u201338. https:\/\/doi.org\/10.1021\/jm401490p.","journal-title":"J Med Chem"},{"issue":"5237","key":"182_CR42","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1126\/science.270.5237.797","volume":"270","author":"SM Russell","year":"1995","unstructured":"Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science. 1995;270(5237):797\u2013800. https:\/\/doi.org\/10.1126\/science.270.5237.797.","journal-title":"Science."},{"issue":"1","key":"182_CR43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1872312810666151223103353","volume":"10","author":"F Namour","year":"2016","unstructured":"Namour F, Desrivot J, Van der Aa A, Harrison P, Tasset C, van't Klooster G. Clinical confirmation that the selective JAK1 inhibitor Filgotinib (GLPG0634) has a low liability for drug-drug interactions. Drug Metab Lett. 2016;10(1):38\u201348. https:\/\/doi.org\/10.2174\/1872312810666151223103353.","journal-title":"Drug Metab Lett"},{"issue":"7","key":"182_CR44","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","volume":"191","author":"L Van Rompaey","year":"2013","unstructured":"Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013;191(7):3568\u201377. https:\/\/doi.org\/10.4049\/jimmunol.1201348.","journal-title":"J Immunol"},{"issue":"10066","key":"182_CR45","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","volume":"389","author":"S Vermeire","year":"2017","unstructured":"Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, et al. Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):266\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(16)32537-5.","journal-title":"Lancet."},{"key":"182_CR46","doi-asserted-by":"publisher","unstructured":"Kavanaugh A, Westhovens RR, Winthrop KL, Lee SJ, Tan Y, An D, et al. Safety and efficacy of filgotinib: Up to 4-year results from an open-label extension study of phase II rheumatoid arthritis programs. J Rheumatol. 2021. https:\/\/doi.org\/10.3899\/jrheum.201183","DOI":"10.3899\/jrheum.201183"},{"issue":"6","key":"182_CR47","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","volume":"76","author":"R Westhovens","year":"2017","unstructured":"Westhovens R, Taylor PC, Alten R, Pavlova D, Enriquez-Sosa F, Mazur M, et al. Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 2017;76(6):998\u20131008. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210104.","journal-title":"Ann Rheum Dis"},{"issue":"26","key":"182_CR48","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1056\/NEJMc1412997","volume":"371","author":"T Hornung","year":"2014","unstructured":"Hornung T, Janzen V, Heidgen FJ, Wolf D, Bieber T, Wenzel J. Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med. 2014;371(26):2537\u20138. https:\/\/doi.org\/10.1056\/NEJMc1412997.","journal-title":"N Engl J Med"},{"issue":"8","key":"182_CR49","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","volume":"152","author":"DJ Kurtzman","year":"2016","unstructured":"Kurtzman DJ, Wright NA, Lin J, Femia AN, Merola JF, Patel M, et al. Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatol. 2016;152(8):944\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2016.0866.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"182_CR50","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/bjd.13915","volume":"173","author":"CO Anyanwu","year":"2015","unstructured":"Anyanwu CO, Fiorentino DF, Chung L, Dzuong C, Wang Y, Okawa J, et al. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol. 2015;173(4):969\u201374. https:\/\/doi.org\/10.1111\/bjd.13915.","journal-title":"Br J Dermatol"},{"issue":"4","key":"182_CR51","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.semarthrit.2016.08.009","volume":"46","author":"JJ Paik","year":"2017","unstructured":"Paik JJ, Christopher-Stine L. A case of refractory dermatomyositis responsive to tofacitinib. Semin Arthritis Rheum. 2017;46(4):e19. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.08.009.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"182_CR52","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/art.20349","volume":"50","author":"LG Rider","year":"2004","unstructured":"Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 2004;50(7):2281\u201390. https:\/\/doi.org\/10.1002\/art.20349.","journal-title":"Arthritis Rheum"},{"key":"182_CR53","unstructured":"\u2022\u2022 Paik JJ, Albayda J, Tiniakou E, Koenig A, Christopher-Stine A. Study of Tofacitinib in refractory dermatomyositis (STIR): an open label pilot study in refractory dermatomyositis. 2018 ACR\/ARHP Annual Meeting. 2018. First clinical trial using tofacitinib in refractory dermatomyositis."},{"issue":"6","key":"182_CR54","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/brain\/awy105","volume":"141","author":"L Ladislau","year":"2018","unstructured":"\u2022\u2022 Ladislau L, Suarez-Calvet X, Toquet S, Landon-Cardinal O, Amelin D, Depp M, et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain. 2018;141(6):1609\u201321. https:\/\/doi.org\/10.1093\/brain\/awy105Comprehensive study describing the the efficacy of ruxolitinib in dermatomyositis.","journal-title":"Brain"},{"issue":"5","key":"182_CR55","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.21023","volume":"52","author":"S Sato","year":"2005","unstructured":"Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52(5):1571\u20136. https:\/\/doi.org\/10.1002\/art.21023.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"182_CR56","first-page":"1719","volume":"32","author":"H Kameda","year":"2005","unstructured":"Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute\/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005;32(9):1719\u201326.","journal-title":"J Rheumatol"},{"issue":"4","key":"182_CR57","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1684\/ejd.2007.0220","volume":"17","author":"Y Kawachi","year":"2007","unstructured":"Kawachi Y, Maruyama H, Furuta J, Fujisawa Y, Nakamura Y, Takahashi T, et al. Cutaneous deep necrosis with dermatomyositis: correlation with interstitial pneumonia. Eur J Dermatol. 2007;17(4):345\u20136. https:\/\/doi.org\/10.1684\/ejd.2007.0220.","journal-title":"Eur J Dermatol"},{"issue":"4","key":"182_CR58","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/MD.0b013e3182606f0b","volume":"91","author":"NF Chaisson","year":"2012","unstructured":"Chaisson NF, Paik J, Orbai AM, Casciola-Rosen L, Fiorentino D, Danoff S, et al. A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature. Medicine (Baltimore). 2012;91(4):220\u20138. https:\/\/doi.org\/10.1097\/MD.0b013e3182606f0b.","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"182_CR59","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","volume":"57","author":"K Kurasawa","year":"2018","unstructured":"Kurasawa K, Arai S, Namiki Y, Tanaka A, Takamura Y, Owada T, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford). 2018;57(12):2114\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/key188.","journal-title":"Rheumatology (Oxford)"},{"key":"182_CR60","doi-asserted-by":"publisher","unstructured":"Kato M, Ikeda K, Kageyama T, Kasuya T, Kumagai T, Furuya H, et al. Successful treatment for refractory interstitial lung disease and pneumomediastinum with multidisciplinary therapy including tofacitinib in a patient with anti-MDA5 antibody-positive dermatomyositis. J Clin Rheumatol. 2019. https:\/\/doi.org\/10.1097\/RHU.0000000000000984.","DOI":"10.1097\/RHU.0000000000000984"},{"issue":"3","key":"182_CR61","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","volume":"381","author":"Z Chen","year":"2019","unstructured":"\u2022\u2022 Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med. 2019;381(3):291\u20133. https:\/\/doi.org\/10.1056\/NEJMc1900045Study showing evidence that tofacitinib may prevent the progression of the interstitial lung disease in patients anti-MDA5 dermatomyositis.","journal-title":"N Engl J Med"},{"key":"182_CR62","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jaut.2019.03.003","volume":"100","author":"S Wendel","year":"2019","unstructured":"Wendel S, Venhoff N, Frye BC, May AM, Agarwal P, Rizzi M, et al. Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib \u2014 a report of two cases. J Autoimmun. 2019;100:131\u20136. https:\/\/doi.org\/10.1016\/j.jaut.2019.03.003.","journal-title":"J Autoimmun"},{"issue":"37","key":"182_CR63","doi-asserted-by":"publisher","first-page":"e21943","DOI":"10.1097\/MD.0000000000021943","volume":"99","author":"Y Ishikawa","year":"2020","unstructured":"Ishikawa Y, Kasuya T, Fujiwara M, Kita Y. Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: a case report. Medicine (Baltimore). 2020;99(37):e21943. https:\/\/doi.org\/10.1097\/MD.0000000000021943.","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"182_CR64","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1093\/brain\/awy255","volume":"141","author":"FA Aeschlimann","year":"2018","unstructured":"Aeschlimann FA, Fremond ML, Duffy D, Rice GI, Charuel JL, Bondet V, et al. A child with severe juvenile dermatomyositis treated with ruxolitinib. Brain. 2018;141(11):e80. https:\/\/doi.org\/10.1093\/brain\/awy255.","journal-title":"Brain."},{"issue":"3","key":"182_CR65","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1093\/brain\/awz005","volume":"142","author":"C Papadopoulou","year":"2019","unstructured":"Papadopoulou C, Hong Y, Omoyinmi E, Brogan PA, Eleftheriou D. Janus kinase 1\/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain. 2019;142(3):e8. https:\/\/doi.org\/10.1093\/brain\/awz005.","journal-title":"Brain."},{"issue":"11","key":"182_CR66","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1093\/brain\/awz293","volume":"142","author":"S Sabbagh","year":"2019","unstructured":"Sabbagh S, Almeida de Jesus A, Hwang S, Kuehn HS, Kim H, Jung L, et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain. 2019;142(11):e59. https:\/\/doi.org\/10.1093\/brain\/awz293.","journal-title":"Brain"},{"key":"182_CR67","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Kim H, Dill S, O'Brien M, Vian L, Li X, Manukyan M, et al. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Ann Rheum Dis. 2020. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218690First clinical trial showing evidence that baricitinib may be effective in patients with refractory juvenile dermatomyositis.","DOI":"10.1136\/annrheumdis-2020-218690"},{"key":"182_CR68","doi-asserted-by":"publisher","unstructured":"Yu Z, Wang L, Quan M, Zhang T, Song H. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review. Rheumatology (Oxford). 2020. https:\/\/doi.org\/10.1093\/rheumatology\/keaa558.","DOI":"10.1093\/rheumatology\/keaa558"},{"issue":"5","key":"182_CR69","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1067\/mpd.2001.112473","volume":"138","author":"M Mukamel","year":"2001","unstructured":"Mukamel M, Horev G, Mimouni M. New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr. 2001;138(5):763\u20136. https:\/\/doi.org\/10.1067\/mpd.2001.112473.","journal-title":"J Pediatr"},{"issue":"11","key":"182_CR70","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1002\/acr.23188","volume":"69","author":"J Albayda","year":"2017","unstructured":"Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L, et al. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res. 2017;69(11):1771\u20136. https:\/\/doi.org\/10.1002\/acr.23188.","journal-title":"Arthritis Care Res"}],"container-title":["Current Treatment Options in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40674-021-00182-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40674-021-00182-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40674-021-00182-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T17:27:45Z","timestamp":1659115665000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40674-021-00182-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["182"],"URL":"https:\/\/doi.org\/10.1007\/s40674-021-00182-1","relation":{},"ISSN":["2198-6002"],"issn-type":[{"value":"2198-6002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]},"assertion":[{"value":"28 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Maria Casal-Dominguez declares that she has no conflict of interest. Iago Pinal-Fernandez declares that he has no conflict of interest. Andrew L. Mammen declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}